Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: A systematic comparison

European Neurology

Volumn 60, Issue 1, 2008, Pages 1-11

  Freedman, Mark S ^a,g   Hughes, Bruce ^b   Mikol, Daniel D ^c   Bennett, Randy ^d   Cuffel, Brian ^e   Divan, Vamil ^e   Lavallee, Nicole ^f   Al Sabbagh, Ahmad ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Research Center   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d EMD SERONO INC   (United States)

^e PFIZER INC   (United States)

^f PROMETRIKA LLC   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Disease modifying therapy; Evidence based medicine; Glatiramer; Interferon beta; Natalizumab; Therapeutic gain

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK FACTOR; RISK REDUCTION;

CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; RECURRENCE; TREATMENT OUTCOME;

EID: 44849088841     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127972     Document Type: Review

References (27)

1. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B: Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74.
2. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B: Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-1506.
3. Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult Scler 2006;12:72-76.
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH; The Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
5. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB; The Copolymer 1 Multiple Sclerosis Study Group: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276.
6. RevMan 4.2 User Guide. Oxford, The Cochrane Collaboration, 2004.
7. SAS/STAT User's Guide, Version 8. Cary, SAS Institute, Inc., 1999.
8. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R, Rice GP: Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552.
9. The Once Weekly Interferon for MS Study Group: Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999;53:679-686.
10. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
11. Miller DH: Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004;1:284-294.
12. Schreiber K, Sorensen PS, Koch-Henriksen N, Wagner A, Blinkenberg M, Svarer C, Petersen HC: Correlations of brain MRI parameters to disability in multiple sclerosis. Acta Neurol Scand 2001;104:24-30.
13. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
15. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
16. Copaxone package insert. Kansas City, Teva Neuroscience, Inc., 2004.
17. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708.
18. Freedman MS, Francis GS, Sanders EA, Rice GP, O'Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, Abramsky O, Pelletier J, O'Brien F: Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005;11:41-45.
19. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G: Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-1496.
20. Tysabri package insert. Cambridge, Biogen Idec, Inc., 2006.
21. Avonex Summary Basis for Approval. Cambridge, Biogen Index Inc., http://www.fda.gov/cder/biologics/sba/ifnbbio051796s.pdf.
22. Rebif Summary Basis for Approval - Statistical Review. Rockland, Serono, Inc., Feb 18, 1999.
23. Li DK, Paty DW: Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999;46:197-206.
24. Betaseron package insert. Emeryville, CA, Chiron Corp., 2003.
25. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
26. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
27. Comi G, Filippi M, Wolinsky JS; European/Canadian Glatiramer Acetate Study Group: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.